News

December 1, 2019

Dear Colleagues and Friends,

Our fourth Alpha Tau Newsletter is full of fantastic updates that I am very excited to share with you.
 
I am thrilled to inform you that our first clinical trial results have been published! The exceptional results were presented in the I...

November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.


Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

October 7, 2019

October 7 is the birth date of Danish physicist Niels Bohr [1] (1885-1862). Bohr has a special significance for Alpha Tau, for two reasons. The first reason is because he was one of the key contributors to the foundational discoveries in atomic physics at the beginning...

July 2, 2019

Dear Colleagues and Friends, 

I am thrilled to share with you our newest developments achieved in the past months - whether it comes to new collaborations, approvals, research or operational developments, Alpha Tau is rapidly progressing!

In the last several weeks, we ha...

April 11, 2019

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016 certification. The certification was awarded following an audit by the UK's independent national compliance body, British St...

February 19, 2019

We are delighted to share with you our first quarterly newsletter of 2019. 

Beyond the great operational progress, our most important advancement this quarter has been the highly promising clinical results from the cancer centers, Rabin Medical Center (RMC) in Israel...

January 31, 2019

Radiation therapy, the use of high-energy particles or waves, such as x-rays, gamma rays, electrons, or protons, has long been used to treat cancer. From as early as the 20th Century, physicians have given regular doses of radiation to greatly improve the patient’s cha...

Cancer is the most devastating chronic disease affecting humankind. More than 1 out of 3 people in the United States will have cancer during their lifetimes, of which 30% of them will die 5 years from diagnosis [i].  As people live longer, the number of new cancer case...

August 23, 2018

The Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), has approved Alpha Tau Medical’s Alpha DaRT cancer treatment as a Sealed Source and Device (SSD). 

https://www.dotmed.com/news/story/44162 

Granting of th...

August 22, 2018

Alpha Tau is in the last stages of raising an investment of several tens of millions of dollars.

Israeli oncology company Alpha Tau Medical Ltd. is in the last stages of raising an investment of several tens of millions of dollars, one person familiar with the matter to...

Please reload

Categories
Please reload

Sign up
Featured Posts